FDG PET/CT for monitoring response to neoadjuvant chemotherapy in breast cancer patients
- 129 Downloads
The recently published study of Straver et al. describes the potential value of FDG PET/CT for monitoring neoadjuvant chemotherapy in a selective population of breast cancer patients.
Several annotations referring to both methodological and clinical aspects need to be made.
Straver et al. claim that a sufficiently prominent visualization of axillary lymph node metastases with FDG PET/CT allows monitoring of the axillary response. Several problems occurred in previous studies investigating the value of FDG PET(/CT) for monitoring response to neoadjuvant chemotherapy in breast cancer patients [1, 2, 3, 4]:
First, various criteria to define tumour response in breast cancer patients have been proposed: response can be assessed clinically and/or pathohistologically. Among the definitions of clinical response, the criteria validated by the Response Evaluation Criteria in Solid Tumours (RECIST) Group in the year 2000 is widely accepted and has been frequently used . For...
KeywordsBreast Cancer Patient Axillary Lymph Node Standardize Uptake Value Axillary Lymph Node Metastasis Positive Axillary Lymph Node
- 5.Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92(3):205–16.CrossRefPubMedGoogle Scholar
- 7.Machiavelli MR, Romero AO, Pérez JE, Lacava JA, Domínguez ME, Rodríguez R, et al. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. Cancer J Sci Am 1998;4(2):125–31.PubMedGoogle Scholar
- 8.Langer I, Guller U, Viehl CT, Moch H, Wight E, Harder F, et al. Axillary lymph node dissection for sentinel lymph node micrometastases may be safely omitted in early-stage breast cancer patients: long-term outcomes of a prospective study. Ann Surg Oncol 2009;16(12):3366–74.CrossRefPubMedGoogle Scholar